ALDER BIOPHARMACEUTICALS INC Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Revenues
Collaboration and license agreements
Operating expenses
Cost of sales
Research and development
General and administrative
Total operating expenses
Gain on license of clazakizumab
Loss from operations
Other income (expense)
Interest income
Interest expense
Foreign currency gain (loss)
Other income
Change in fair value of derivative liability
Total other income (expense), net
Net loss before equity in net loss of unconsolidated entity
Equity in net loss of unconsolidated entity
Net loss
Net income (loss) per share - diluted
Weighted average number of common shares used in net income (loss) per share - diluted
Deemed dividends on convertible preferred stock attributable to accretion of beneficial conversion feature
Dividends on convertible preferred stock
Net loss applicable to common stockholders
Net loss per share applicable to common stockholders - basic and diluted
Weighted average number of common shares used in net loss per share - basic and diluted

Comments